A chance for the US regulator to show its teeth, at Amag’s expense
An advisory panel votes to pull Amag’s Makena from the market, but will the US regulator follow through?
Reneuron’s reinvention falters
More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.
TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Esmo 2019 – Opdivo could have done better in liver cancer
A post-mortem of Bristol’s first-line trial suggests that patients’ PD-L1 status should have been taken into consideration, though Roche hopes it too can do without such…
ESC 2019 – Astra’s latest Brilinta hopes bleed out on full Themis data
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.
ESC 2019 – Trial failure leaves Cellaegis in limbo
Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.
ESC 2019 – Novartis sees reasons to push on post-Paragon
With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.
Neptune leaves Astra at sea
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.